MIMEDX GROUP, INC. 8K

MiMedx Group, Inc. agreed to acquire Sanara MedTech Inc. for approximately $350 million in a cash-and-stock deal to expand its surgical business, financed partly by a new $300 million term loan and expected to close by year-end 2026, subject to approvals.

On July 29, 2026, MiMedx Group, Inc. announced an agreement to acquire Sanara MedTech Inc. for approximately $350 million in a cash-and-stock transaction, under which Sanara shareholders will receive $35 per share (comprised of $33 in cash and 0.4735 shares of MiMedx common stock valued at $2.00), financed through a combination of MiMedx’s cash on hand and a fully committed $300 million senior secured term loan from Hayfin Capital Management, LLP. The combination is intended to significantly expand MiMedx’s surgical footprint across soft tissue and musculoskeletal categories, add roughly $100 million of surgical revenue, unlock an estimated $4 billion of incremental total addressable markets via Sanara’s 510(k) portfolio, and generate more than $20 million of annualized run-rate cost synergies by 2027, with management expecting combined 2027 revenue well in excess of $400 million and adjusted EBITDA margins above 20%. The boards of directors of both companies have unanimously approved the transaction, which is expected to close by year-end 2026, subject to Sanara shareholder approval, customary regulatory approvals and other closing conditions, and MiMedx plans to file a Form S-4 registration statement while Sanara will file a proxy statement on Schedule 14A in connection with the deal.

Filing Facts

CIK

1376339

Ticker

-

Form

8K

Source Type

sec

Accession

0001376339-26-000074

Alert Tier

8